 |
市場調查報告書
商品編碼
1550612
全球原發性硬化性膽管炎市場：依藥物類別、給藥途徑、通路及地區Primary sclerosing cholangitis Market, By Drug Class (Ursodeoxycholic acid, Corticosteroids, Azathioprine, Mercaptopurine, Budesonide, Obeticholic acid, Monoclonal antibody, Others), By Route of Administration, By Distribution Channel, By Geography |
||||||
預計2024年全球原發性硬化性膽管炎市場規模將達1.612億美元，2024年至2031年複合年成長率為7.8%，2031年將達2.731億美元。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2023年 | 2024年市場規模 | 1.612 億美元 |
| 實際資料 | 2019-2023 | 預測期 | 2024-2031 |
| 預測 2024-2031 年複合年成長率： | 7.80% | 2031 年金額預測 | 2.731 億美元 |
原發性硬化性膽管炎（PSC）是一種慢性進行性膽汁淤積性肝病，其特徵是肝內和肝外膽管多灶性狹窄和纖維化。 70% 至 80% 的病例存在發炎性腸道疾病（通常是潰瘍性大腸炎）。儘管 PSC 的確切原因尚不清楚，但它被認為是一種自體免疫疾病，由遺傳易感性和環境觸發因素的複雜相互作用引起。 PSC 的全球盛行率估計為每 10 萬人中 13 至 16 人。目前，PSC 尚無治療方法，治療重點是減輕症狀和減緩疾病進展。全球原發性硬化性膽管炎市場的成長是由診斷率上升和醫療保健支出增加所推動的。
市場動態：
原發性硬化性膽管炎的全球市場成長是由人們對該疾病的認知不斷提高、先進診斷方法提高診斷率以及全球易患 PSC 的老年人口增加等因素推動的。然而，缺乏核准治療 PSC 的藥物以及發病機制的複雜性可能會阻礙市場成長。持續研發新療法和增加新興市場的醫療保健支出可以為市場參與企業帶來巨大的商機。
本研究的主要特點
該報告對全球原發性硬化性膽管炎市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。
它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球原發性膽管炎市場的主要企業進行了分析。
本研究涵蓋的主要企業包括 Intercept Pharmaceuticals、Dr. Falk Pharma GmbH 和 Acorda Therapeutics Inc。
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球原發性硬化性膽管炎市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球原發性硬化性膽管炎市場的各種策略矩陣，將促進相關人員的決策。
目錄
第1章 研究目的與前提
- 研究目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規及趨勢分析
- 市場動態
- 促進因素
- 抑制因素
- 機會
- 影響分析
- 市場趨勢
- 主要進展
- 監管場景
- 收購和合作場景
- 資金籌措和投資
- PEST分析
- 波特的分析
第4章全球原發性硬化性膽管炎市場－COVID-19 的影響
- 整體影響
- 政府舉措
- COVID-19 對市場的影響
第5章全球原發性硬化性膽管炎市場，依藥物類別，2019-2031（百萬美元）
- 熊去氧膽酸 (UDCA)
- 皮質類固醇
- Azathioprine
- Mercaptopurine
- Budesonide
- 奧貝膽酸
- 單株抗體
- 其他
第6章 全球原發性硬化性膽管炎市場，依給藥途徑，2019-2031 年（百萬美元）
- 口服
- 胃腸外的
- 其他
第7章 全球原發性硬化性膽管炎市場，依分銷管道分類，2019-2031 年（百萬美元）
- 醫院藥房
- 零售藥房
- 網路藥房
第8章全球原發性硬化性膽管炎市場，按地區，2019-2031（百萬美元）
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
第9章 競爭格局
- 公司簡介
- Acorda Therapeutics, Inc.
- Gilead Sciences, Inc.
- NGM Biopharmaceuticals, Inc.
- Intercept Pharmaceuticals, Inc.
- Dr. Falk Pharma GmbH
- Allergan Plc.
- Shire Plc.
- Durect Corporation
- Conatus Pharmaceuticals, Inc.
- Sirnaomics, Inc.
- Shenzhen HighTide Biopharmaceutical Ltd.
- Cymabay Therapeutics
- Pliant Therapeutics
- Immunic AG
第10章分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第11章 參考文獻與調查方法
- 參考
- 調查方法
Global primary sclerosing cholangitis market is estimated to be valued at USD 161.2 Mn in 2024 and is expected to reach USD 273.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 161.2 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 7.80% | 2031 Value Projection: | US$ 273.1 Mn |
Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease characterized by multifocal strictures and fibrosis of the intrahepatic and extrahepatic bile ducts. It is associated with inflammatory bowel disease, usually ulcerative colitis, in 70-80% of cases. The exact cause of PSC remains unknown, but it is believed to be an autoimmune disease resulting from a complex interplay between genetic susceptibility and environmental triggers. The global prevalence of PSC is estimated to range between 13-16 cases per 100,000 individuals. Currently, there is no cure for PSC and treatment is focused on relieving symptoms and slowing disease progression. Global primary sclerosing cholangitis market growth is driven by increasing diagnosis rates and rising healthcare expenditure.
Market Dynamics:
Global primary sclerosing cholangitis market growthis driven by factors like rising awareness about the disease, increasing diagnosis rates attributed to advanced diagnostic modalities, and growing geriatric population worldwide who are more susceptible to develop PSC. However, lack of an approved drug for treating PSC and complexities associated with the disease pathogenesis can hamper the market growth. Ongoing R&D for developing novel therapeutics and increasing healthcare expenditures in emerging nations can present high-impact profitable opportunities for market players.
Key Features of the Study:
This report provides in-depth analysis of the global primary sclerosing cholangitis market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global primary sclerosing cholangitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Intercept Pharmaceuticals, Dr. Falk Pharma GmbH, and Acorda Therapeutics Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary sclerosing cholangitis market
Detailed Segmentation-
- By Drug Class
- Ursodeoxycholic acid (UDCA)
- Corticosteroids
- Azathioprine
- Mercaptopurine
- Budesonide
- Obeticholic acid
- Monoclonal antibody
- Others
- By Route of Administration
- Oral
- Parenteral
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Acorda Therapeutics, Inc.
- Gilead Sciences, Inc.
- NGM Biopharmaceuticals, Inc.
- Intercept Pharmaceuticals, Inc.
- Falk Pharma GmbH
- Allergan Plc.
- Shire Plc.
- Durect Corporation
- Conatus Pharmaceuticals, Inc.
- Sirnaomics, Inc.
- Shenzhen HighTide Biopharmaceutical Ltd.
- Cymabay Therapeutics
- Pliant Therapeutics
- Immunic AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Primary Sclerosing Cholangitis Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Primary Sclerosing Cholangitis Market, By Drug Class, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Ursodeoxycholic acid (UDCA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Azathioprine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Mercaptopurine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Budesonide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Obeticholic acid
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Monoclonal antibody
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Global Primary Sclerosing Cholangitis Market, By Route of Administration, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Global Primary Sclerosing Cholangitis Market, By Distribution Channel, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
8. Global Primary Sclerosing Cholangitis Market, By Region, 2019 - 2031, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Acorda Therapeutics, Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Gilead Sciences, Inc.
- NGM Biopharmaceuticals, Inc.
- Intercept Pharmaceuticals, Inc.
- Dr. Falk Pharma GmbH
- Allergan Plc.
- Shire Plc.
- Durect Corporation
- Conatus Pharmaceuticals, Inc.
- Sirnaomics, Inc.
- Shenzhen HighTide Biopharmaceutical Ltd.
- Cymabay Therapeutics
- Pliant Therapeutics
- Immunic AG
- Acorda Therapeutics, Inc.
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
